Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
NorthShore University Health System
mi
from
Evanston, IL
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
NorthShore University Health System
mi
from
Evanston, IL
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/8/2017
Virginia Mason
mi
from
Seattle, WA
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/8/2017
Virginia Mason
mi
from
Seattle, WA
Click here to add this to my saved trials
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/14/2017
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/14/2017
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/14/2017
Montefiore Medical Center
mi
from
New York, NY
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/14/2017
Montefiore Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
Mayo Clinic Cancer Center
mi
from
Scottsdale, AZ
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
Mayo Clinic Cancer Center
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
University of Southern California- Keck School of Medicine
mi
from
Los Angeles, CA
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
University of Southern California- Keck School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
UC Davis Medical Center
mi
from
Sacramento, CA
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
UC Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
University of Colorado Denver
mi
from
Aurora, CO
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
Oschner Medical Center
mi
from
Kenner, LA
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
Oschner Medical Center
mi
from
Kenner, LA
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
Henry Ford Health System
mi
from
Detroit, MI
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
SUNY Downstate Medical Center
mi
from
Brooklyn, NY
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
SUNY Downstate Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
Weill-Cornell Medical College
mi
from
New York, NY
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
Southwestern Regional Medical Center
mi
from
Tulsa, OK
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
Southwestern Regional Medical Center
mi
from
Tulsa, OK
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
Allegheny Center for Digestive Health - AHN ASRI
mi
from
Pittsburgh, PA
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
Allegheny Center for Digestive Health - AHN ASRI
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
Methodist Dallas Medical Center
mi
from
Dallas, TX
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
Methodist Dallas Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
Virginia Mason Medical Center
mi
from
Seattle, WA
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
St. Michael's Hospital
mi
from
Toronto,
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
St. Michael's Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated:  12/18/2017
Columbia University Medical Center
mi
from
New York, NY
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Status: Enrolling
Updated: 12/18/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Isolated Liver Perfusion With Oxaliplatin
A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases
Status: Enrolling
Updated:  12/19/2017
UPMC Presbyterian
mi
from
Pittsburgh, PA
Isolated Liver Perfusion With Oxaliplatin
A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases
Status: Enrolling
Updated: 12/19/2017
UPMC Presbyterian
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Isolated Liver Perfusion With Oxaliplatin
A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases
Status: Enrolling
Updated:  12/19/2017
UPMC Cancer Centers, Hillman Cancer Center
mi
from
Pittsburgh, PA
Isolated Liver Perfusion With Oxaliplatin
A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases
Status: Enrolling
Updated: 12/19/2017
UPMC Cancer Centers, Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Isolated Liver Perfusion With Oxaliplatin
A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases
Status: Enrolling
Updated:  12/19/2017
UPMC - Shadyside
mi
from
Pittsburgh, PA
Isolated Liver Perfusion With Oxaliplatin
A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases
Status: Enrolling
Updated: 12/19/2017
UPMC - Shadyside
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Follow-up Yttrium-90 Internal Pair Production PET/CT vs Brehmsstrahlung Imaging in Patients With Primary/Metastatic Liver Tumors
Follow-up Yttrium-90 Internal Pair Production PET/CT Imaging in Patients With Primary or Metastatic Liver Tumors as Compared With Brehmsstrahlung Imaging: A Prospective Case Series
Status: Enrolling
Updated:  12/27/2017
Jackson Health System
mi
from
Miami, FL
Follow-up Yttrium-90 Internal Pair Production PET/CT vs Brehmsstrahlung Imaging in Patients With Primary/Metastatic Liver Tumors
Follow-up Yttrium-90 Internal Pair Production PET/CT Imaging in Patients With Primary or Metastatic Liver Tumors as Compared With Brehmsstrahlung Imaging: A Prospective Case Series
Status: Enrolling
Updated: 12/27/2017
Jackson Health System
mi
from
Miami, FL
Click here to add this to my saved trials
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Phase Ib Clinical Trial of Sorafenib in Combination With Transarterial Chemoembolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  1/3/2018
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Phase Ib Clinical Trial of Sorafenib in Combination With Transarterial Chemoembolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 1/3/2018
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Phase Ib Clinical Trial of Sorafenib in Combination With Transarterial Chemoembolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  1/3/2018
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Phase Ib Clinical Trial of Sorafenib in Combination With Transarterial Chemoembolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 1/3/2018
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Randomized Phase II Trial of Chemoembolization and Sorafenib
Randomized Phase II Trial of Chemoembolization and Sorafenib: Comparison Between Continuous and Sequential Treatment Regimens
Status: Enrolling
Updated:  1/8/2018
Smilow Cancer Center
mi
from
New Haven, CT
Randomized Phase II Trial of Chemoembolization and Sorafenib
Randomized Phase II Trial of Chemoembolization and Sorafenib: Comparison Between Continuous and Sequential Treatment Regimens
Status: Enrolling
Updated: 1/8/2018
Smilow Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Clinical Application of Image-Guided Liver Surgery
Clinical Application of Image-Guided Liver Surgery
Status: Enrolling
Updated:  1/16/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Clinical Application of Image-Guided Liver Surgery
Clinical Application of Image-Guided Liver Surgery
Status: Enrolling
Updated: 1/16/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases
Dose Escalating Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases
Status: Enrolling
Updated:  1/22/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases
Dose Escalating Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases
Status: Enrolling
Updated: 1/22/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases
Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver
Status: Enrolling
Updated:  1/22/2018
Northwestern University
mi
from
Chicago, IL
Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases
Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver
Status: Enrolling
Updated: 1/22/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC)
A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C
Status: Enrolling
Updated:  1/23/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC)
A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C
Status: Enrolling
Updated: 1/23/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Stereotactic Body Radiotherapy for Liver Tumors
Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Liver Metastases and Primary Liver Tumors
Status: Enrolling
Updated:  1/24/2018
St John's Mercy Medical Center
mi
from
Saint Louis, MO
Stereotactic Body Radiotherapy for Liver Tumors
Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Liver Metastases and Primary Liver Tumors
Status: Enrolling
Updated: 1/24/2018
St John's Mercy Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
A Phase I Trial of Epirubicin, Carboplatin and Capecitabine in Adult Cancer Patients
Status: Enrolling
Updated:  1/24/2018
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
A Phase I Trial of Epirubicin, Carboplatin and Capecitabine in Adult Cancer Patients
Status: Enrolling
Updated: 1/24/2018
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery
A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers
Status: Enrolling
Updated:  1/26/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery
A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers
Status: Enrolling
Updated: 1/26/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
A Phase I Study of High-Dose Oral Vitamin D for the Prevention of Hepatocellular Carcinoma in Subjects With Cirrhosis
Status: Enrolling
Updated:  1/30/2018
Sibley Memorial Hospital /Johns Hopkins University
mi
from
Washington,
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
A Phase I Study of High-Dose Oral Vitamin D for the Prevention of Hepatocellular Carcinoma in Subjects With Cirrhosis
Status: Enrolling
Updated: 1/30/2018
Sibley Memorial Hospital /Johns Hopkins University
mi
from
Washington,
Click here to add this to my saved trials
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
Intrinsic Dosimetry for Radioembolization Utilizing PET-CT Imaging Data: A Prospective Registry Study
Status: Enrolling
Updated:  2/8/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
Intrinsic Dosimetry for Radioembolization Utilizing PET-CT Imaging Data: A Prospective Registry Study
Status: Enrolling
Updated: 2/8/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
Validation Study of Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
Status: Enrolling
Updated:  2/13/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
Validation Study of Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
Status: Enrolling
Updated: 2/13/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/13/2018
Indiana University
mi
from
Indianapolis, IN
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/13/2018
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/13/2018
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/13/2018
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/13/2018
NYU Langone Medical Center; Bellevue Hospital
mi
from
New York, NY
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/13/2018
NYU Langone Medical Center; Bellevue Hospital
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/13/2018
Weill-Cornell Medical College
mi
from
New York, NY
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/13/2018
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/13/2018
Columbia University Medical Center
mi
from
New York, NY
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/13/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/13/2018
Gabrail Cancer Center
mi
from
Canton, OH
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/13/2018
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/13/2018
Ohio State University
mi
from
Columbus, OH
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/13/2018
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
A Phase II Multi-center Study Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and Sylatron (Peginterferon Alfa-2b) HCRN:GI16-263
Status: Enrolling
Updated:  2/13/2018
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
A Phase II Multi-center Study Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and Sylatron (Peginterferon Alfa-2b) HCRN:GI16-263
Status: Enrolling
Updated: 2/13/2018
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma
A Phase III, Multicenter, Open-Label, Randomized Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablated Intra-Hepatic Cholangiocarcinoma
Status: Enrolling
Updated:  2/15/2018
University of Louisville
mi
from
Louisville, KY
A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma
A Phase III, Multicenter, Open-Label, Randomized Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablated Intra-Hepatic Cholangiocarcinoma
Status: Enrolling
Updated: 2/15/2018
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials